Serious adverse events were reported for 10.1 percent of patients receiving 0.5 mg of fingolimod, 11.9 percent of these receiving 1.25 mg of fingolimod, and 13.4 percent of those receiving placebo. The most typical serious adverse events, each reported for eight individuals, were bradycardia, multiple sclerosis relapse, and basal-cell carcinoma. All other serious adverse events occurred in four or fewer patients in virtually any research group. The seven episodes of bradycardia in both fingolimod groups were reported during the monitoring period following administration of the first dose. Six of these occasions were asymptomatic; the individuals continued to receive fingolimod and the episodes had been reported as significant adverse events as the protocol-defined discharge criteria for the first-dosage monitoring period were not met.Nevertheless, a Thomson Reuters Health care study demonstrated the U.S. Health-care system could save $3.5 billion annually and dramatically reduce hospitalizations and amputation if every American at risk for developing a diabetic foot ulcer visited a podiatrist once, before complications set in. To help spread the word about essential connections between foot health and diabetes, APMA will take to Twitter for a ‘Tweet Your Socks Off’ event on Globe Diabetes Day, 14 November. Users can follow @APMAtweets and ask questions about foot diabetes and care in English and Spanish, and have questions answered by a podiatrist.